EXOR NV will increase its stake in BIOMERIEUX to 8.53% from 3.87% through an asset exchange. The transaction positions the investment firm as a long-term shareholder in the France-based diagnostics maker. Italy's Agnelli family controls the investment company, which holds a 10% stake in BIOMERIEUX's parent.
Exor to Raise bioMerieux Stake
Investment company Exor plans to increase its stake in French biotechnology firm bioMérieux to over eight percent. The transaction involves an exchange of shares and voting rights. The deal is expected to be completed in December.
Xurve View
Insights:
Xurve View








